perpetuity. It is made available under a CC-BY-NC 4.0 International license .

1

1 Combining full-length gene assay and SpliceAI to interpret the splicing impact

2 of all possible SPINK1 coding variants

- 3
- 4 Hao Wu,^{1,2,*} Jin-Huan Lin,^{1,2,*} Xin-Ying Tang,^{3,2*} Wen-Bin Zou,^{1,2} Sacha Schutz,^{4,5} Emmanuelle
- 5 Masson,^{4,5} Yann Fichou,⁴ Gerald Le Gac,^{4,5} Claude Férec,⁴ Zhuan Liao,^{1,2,§} Jian-Min Chen^{4,§}
- 6
- ⁷ ¹Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China.
- 8 ²Shanghai Institute of Pancreatic Diseases, Shanghai, China.
- ³Department of Prevention and Health Care, Eastern Hepatobiliary Surgery Hospital, Naval Medical
- 10 University, Shanghai, China.
- ⁴Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France.
- 12 ⁵CHRU Brest, F-29200 Brest, France.
- 13
- ^{*}These authors share co-first authorship.
- 15

16 **§Correspondence**:

- 17 Jian-Min Chen, Univ Brest, Inserm, EFS, UMR 1078, GGB, 22 avenue Camille Desmoulins, 29238
- 18 BREST, France. Email: jian-min.chen@univ-brest.fr
- 19 Zhuan Liao, Department of Gastroenterology, Changhai Hospital, Naval Medical University, 168
- 20 Changhai Road, Shanghai 200433, China. E-mail: liaozhuan@smmu.edu.cn
- 21

22 Abstract

- 23 Background: Single-nucleotide variants (SNVs) within gene coding sequences can significantly impact
- 24 pre-mRNA splicing, bearing profound implications for pathogenic mechanisms and precision
- 25 medicine. However, reliable splicing analysis often faces practical limitations, especially when the
- relevant tissues are challenging to access. While *in silico* predictions are valuable, they alone do not
- 27 meet clinical classification standards. In this study, we aim to harness the well-established full-length
- 28 gene splicing assay (FLGSA) in conjunction with SpliceAI to prospectively interpret the splicing effects
- of all potential coding SNVs within the four-exon *SPINK1* gene, a gene associated with chronic
- 30 pancreatitis.
- 31 **Results:** We initiated the study with a retrospective correlation analysis (involving 27 previously
- 32 FLGSA-analyzed SPINK1 coding SNVs), progressed to a prospective correlation analysis (incorporating
- 33 35 newly FLGSA-tested SPINK1 coding SNVs), followed by data extrapolation, and ended with further
- 34 van Earlin in the second by search by search by second fight share the second secon

2

35	SNVs and affecting 19.2% of the 240 coding nucleotides. Among these 67 FLGSA-analyzed SNVs, 12
36	were found to impact splicing. Through extensive cross-correlation of the FLGSA-obtained and
37	SpliceAI-predicted data, we reasonably extrapolated that none of the unanalyzed 653 coding SNVs in
38	the SPINK1 gene are likely to exert a significant effect on splicing. Out of these 12 splice-altering
39	events, nine produced both wild-type and aberrant transcripts, while the remaining three exclusively
40	generated aberrant transcripts. These splice-altering SNVs were predominantly concentrated in
41	exons 1 and 2, particularly affecting the first and/or last coding nucleotide of each exon. Among the
42	12 splice-altering events, 11 were missense variants, constituting 2.17% of the 506 potential
43	missense variants, while one was synonymous, accounting for 0.61% of the 164 potential
44	synonymous variants.
45	Conclusions: Integrating FLGSA with SpliceAI, we conclude that less than 2% (1.67%) of all possible
46	SPINK1 coding SNVs have a discernible influence on splicing outcomes. Our findings underscore the
47	importance of performing splicing analysis in the broader genomic sequence context of the study
48	gene, highlight the inherent uncertainties associated with intermediate SpliceAI scores (i.e., those
49	ranging from 0.20 to 0.80), and have general implications for the shift from "retrospective" to
50	"prospective" analysis in terms of variant classification.
51	
52	Keywords: Chronic pancreatitis, In silico prediction, Full-length gene splicing assay, Missense variant,

53 Precision medicine, Pre-mRNA splicing, Single-nucleotide variant, SpliceAI, Splice site, SPINK1

54

55 Background

56 Single-nucleotide variants (SNVs) within the coding sequences of genes have the potential to exert a 57 profound influence on pre-mRNA splicing. Remarkably, approximately 10% of disease-associated 58 missense variants have been recognized as having the capacity to modulate pre-mRNA splicing [1]. 59 This influence goes beyond missense variants and includes synonymous and nonsense variants [2, 3]. 60 These findings have far-reaching implications for our understanding of disease pathogenesis and the 61 advancement of precision medicine. For instance, what was once considered a 'neutral' missense 62 variant or a 'synonymous' variant may, upon closer examination, be found to be disease-causing or related due to its impact on splicing. Similarly, the effectiveness of molecular treatment strategies 63 targeting specific 'missense' or 'nonsense' variants may be compromised if these variants 64 65 unexpectedly affect splicing.

The ideal approach for investigating the splicing effects of clinically detected SNVs is the analysis
of RNA from pathophysiologically relevant tissues. However, practical constraints often limit access
to these tissue samples [4]. As an alternative, RNA analysis from patient blood cells or immortalized

lymphoblastoid cells is commonly employed, under the assumption that the gene of interest exhibits

normal expression in these cell types [5]. When these options prove unfeasible, the frequently

acknowledge the inherent limitation of this assay – its inability to capture the broader genomic

employed approach is the cell culture-based minigene splicing assay [6]. It is essential to

69

70

71

72

73 context of the study gene. This limitation could lead to erroneous findings [7, 8] due to the intricate 74 nature of splicing regulation [9, 10]. 75 In recent years, there have been significant advancements in the prediction of splicing outcomes 76 for SNVs. An outstanding example is SpliceAI [11], a 32-layer deep neural network widely recognized 77 as the most accurate tool for predicting splicing variants currently available (e.g., [12-15]). While 78 these in silico prediction tools are valuable, they cannot be used in isolation to establish 79 pathogenicity in accordance with variant classification guidelines recommended by the American 80 College of Medical Genetics and Genomics (ACMG) [16]. Instead, they serve as first-line tools for 81 variant classification and prioritization. 82 Another critical concern in the realm of precision medicine is the retrospective nature of functional analyses conducted on clinically identified variants [17]. This issue becomes increasingly 83 urgent in an era when exome and genome sequencing have become integral to clinical diagnostics. 84 85 Addressing this challenge requires a shift toward the prospective assessment of the functional impact of all potential SNVs at clinically significant loci in the human genome [18]. Multiplexed assays for 86 87 variant effects (MAVE) offer a solution by enabling systematic collection of functional data for a 88 multitude of variants in a single experiment [19]. A notable example is the prospective assessment of 89 the functional impact, including splicing, of nearly 4,000 single nucleotide substitutions across 13 90 exons of the 24-exon BRCA1 gene [20]. However, MAVE is technically and resource demanding, 91 limiting its widespread application in many laboratories. 92 SPINK1 (OMIM #167790) stands out as one of the primary genes associated with chronic 93 pancreatitis [21]. Located on chromosome 5q32, the pathologically relevant SPINK1 mRNA isoform 94 (NM 001379610.1) comprises four exons, encoding a 79-amino acid precursor protein that 95 eventually yields the mature 56-amino-acid pancreatic secretory trypsin [22, 23]. Loss-of-function 96 variants in the SPINK1 gene increase susceptibility to chronic pancreatitis through the trypsin-97 dependent pathway [21, 24, 25]. Previously, we successfully cloned the ~7-kb genomic sequence of 98 the four-exon SPINK1 gene into the pcDNA3.1/V5-His-TOPO vector, establishing a cell culture-based 99 full-length gene splicing assay (FLGSA) [26]. Notably, FLGSA, unlike the frequently used minigene 100 assay, preserves the broader natural genomic context of the gene under investigation—a crucial 101 factor considering the intricacies of splicing regulation. Naturally, FLGSA also provides a practical 102 advantage over the minigene assay, enabling comprehensive analysis of all coding and intronic 103 variants within a consistent genomic framework.

104 In the context of the SPINK1 gene, we have previously employed the FLGSA assay to analyze both 105 known coding and intronic variants [7, 27-31]. The accuracy of the FLGSA assay is illuminated by the 106 study of the SPINK1 c.194+2T>C variant, a type of variant often considered to cause a complete 107 functional loss of the affected allele due to its occurrence within the canonical GT splice donor site [32]. Specifically, the findings from the FLGSA assay [27] were in alignment with in vivo splicing data 108 109 [33] for c.194+2T>C, revealing a notable presence of wild-type (WT) transcripts alongside with exon 3-skipping aberrant transcripts (N.B. the ratio of WT transcripts to aberrant transcripts was 110 111 subsequently estimated to be 1:9 [34]). Remarkably, this preservation of 10% residual function was 112 associated with the less severe phenotypes observed in SPINK1 c.194+2T>C homozygotes, who 113 exhibit chronic pancreatitis with variable expressivity [35]. In contrast, homozygous SPINK1 variants 114 leading to a complete 100% loss of the gene product are linked to a more severe phenotype referred 115 to as severe infantile isolated exocrine pancreatic insufficiency [36]. 116 In this study, we set out to harness the combined power of the FLGSA assay and SpliceAl's 117 predictive capabilities to prospectively interpret the splicing effects of all potential coding SNVs 118 within the SPINK1 gene. 119 Methods 120


121 Research rationale and strategy

122 The primary objective of this study was to prospectively interpret the splicing impact of all potential 123 coding SNVs within the SPINK1 gene by leveraging a synergistic combination of the FLGSA assay and 124 SpliceAI predictions. Our hypothesis was grounded in the belief that insights derived from correlating 125 experimental data obtained through FLGSA with SpliceAI predictions for a subset of SPINK1 coding SNVs could be reasonably extrapolated to the broader pool of unanalyzed SPINK1 coding SNVs. The 126 127 study would begin with a retrospective correlation analysis (using previously FLGSA-analyzed SPINK1 128 coding SNVs), advance to a prospective correlation analysis (involving newly FLGSA-tested SPINK1 129 coding SNVs), followed by data extrapolation, and end with further validation (Fig. 1).

130

131 SpliceAl

132 SpliceAI provides four Δ scores: acceptor gain (AG), acceptor loss (AL), donor gain (DG), and donor loss (DL). These scores represent the maximum difference between the probability of the variant and 133 134 the reference alleles concerning splice-altering. The Δ score ranges from 0 to 1, with higher scores indicating a greater likelihood that the variant affects splicing. Variants with a Δ score of <0.20 were 135 136 generally considered unlikely to have a substantial impact on splicing, while variants with a Δ score exceeding 0.80 were generally associated with a high specificity for splicing alterations [11]. SpliceAI 137



139

140 Figure 1. Overview of the FLGSA assay and research strategy. a Representation of the SPINK1 full-141 length gene expression vector and the experimental steps involved in the FLGSA assay for each study variant. The coding sequences of the four-exon SPINK1 gene are to scale, while the intronic and 142 143 untranslated region sequences are not. The reference SPINK1 genomic sequence is NG_008356.2, and the reference SPINK1 mRNA sequence is MANE (Matched Annotation from the NCBI and EMBL-EBI 144 145 [37]) select ENST00000296695 or NM_001379610.1. NM_001379610.1 represents the SPINK1 transcript isoform expressed in the exocrine pancreas. The starting and ending positions of the coding 146 147 sequences in each exon, as well as those of the SPINK1 genomic sequence cloned into the 148 pcDNA3.1/V5-His-TOPO vector, are indicated in accordance with NM 001379610. b Illustration 149 demonstrating how the FLGSA assay was integrated with SpliceAI to prospectively evaluate the splicing effects of all potential coding variants within the SPINK1 gene. Abbreviations: FLGSA, full-length gene 150 151 splicing assay; RT-PCR, reverse transcription-PCR; SNVs, single-nucleotide variants.

152

153 also provides the pre-mRNA positions of the predicted splicing effect with respect to the variant

154 position. For SPINK1 variants, positive and negative pre-mRNA positions indicate positions 5' and 3'

155 to the variant position in terms of the gene's sense strand.

156 Our retrospective analysis involved comparing FLGSA data with SpliceAI predictions for known

157 SPINK1 coding SNVs. For our prospective analysis, we selected new SPINK1 coding SNVs for FLGSA

6

analysis based on SpliceAI-predicted Δ scores. These steps relied on SpliceAI Δ scores obtained from
[38] using the default settings of SpliceAI in February 2020. These SpliceAI Δ scores correspond to
Illumina precomputed scores created using Gencode v24 and max distance = 50bp at the time [11]
and align with those accessible to academic users on the SpliceAI Virtual website [39]. Importantly, in
May 2023, SpliceAI retired these Illumina precomputed scores. To adapt to this change and refine the

- 163 cross-correlation, we additionally conducted a second-step analysis for *SPINK1* coding SNVs that
- underwent the FLGSA assay, utilizing SpliceAI Δ scores obtained from SpliceAI Lookup [40] with the
- 165 following parameters: (i) Genome version, hg38; (ii) Score type, Raw; and (iii) Max distance, 10,000.
- 166 This new set of SpliceAl Δ scores was manually obtained in October 2023.
- 167

168 Collation of known SPINK1 coding variants with FLGSA data

- 169 To date, the FLGSA assay has been employed to analyze 27 clinically identified SPINK1 coding SNVs,
- 170 comprising 24 missense variants and 3 synonymous variants [7, 31]. All these 27 variants were
- 171 included in our retrospective correlation analysis.
- 172

173 Selection of potential SPINK1 coding variants for FLGSA

- 174 We conducted a rigorous selection process to identify potential *SPINK1* coding variants for FLGSA.
- 175 This process involved a comprehensive assessment of Illumina precomputed SpliceAI Δ scores for all
- 176 720 potential coding SNVs, which arose from the multiplication of 240 coding nucleotides by 3,
- 177 within the SPINK1 gene. As a general guideline, we chose to encompass all three possible SNVs at the
- beginning (with the exception of exon 1) and end (excluding exon 4) of each exon, regardless of their
- 179 SpliceAI Δ scores. Additionally, we included SNVs with at least one SpliceAI Δ score \geq 0.20, excluding
- 180 those deemed physiologically irrelevant. Furthermore, we incorporated some variants predicted to
- 181 have no impact on splicing as controls. This process initially led us to select 35 SNVs. For the purpose
- 182 of further validation, we selected additional five SNVs for FLGSA. More detailed information is
- 183 provided in the *Results* section.
- 184

185 **FLGSA**

- 186 The newly selected SPINK1 coding SNVs underwent FLGSA analysis, as previously described [27, 29,
- 187 32]. Specifically, the introduction of the selected variants into the full-length gene expression vector
- 188 containing the WT *SPINK1* genomic sequence [26] and the subsequent confirmation of the
- 189 introduced variants through Sanger sequencing were executed by GENEWIZ Biotech Co. (Suzhou,
- 190 China). All subsequent experimental procedures were conducted at the Shanghai Changhai
- 191 laboratory.
- 192

7

193 Cell culture, transfection, RNA extraction, and reverse transcription (RT)

194 Human embryonic kidney 293T (HEK293T) cells were cultured in the DMEM basic medium (Gibco) 195 with 10% fetal calf serum (Procell). 3.5×10^5 cells were seeded per well in 6-well plates 24 hours 196 before transfection. 2.5 µg of either WT or variant plasmid, mixed with HieffTrans Universal Transfection Reagent (Yeasen), was used for transfection per well. Forty-eight hours after 197 transfection, total RNA was extracted using the FastPure Cell/Tissue Total RNA Isolation Kit V2 198 199 (+gDNA wiper) (Vazyme). RT was carried out using the HiScript III 1st Strand cDNA Synthesis Kit 200 (Vazyme), incorporating 2 µL of 5 × gDNA wiper Mix, 2 µL of 10 × RT Mix, 2 µL of HiScript III Enzyme 201 Mix, 1 µL of Oligo (dT)20VN, and 1 µg of total RNA.

202

203 **RT-PCR** and sequencing of the resulting products

204 RT-PCR was performed in a 25- μ L reaction mixture containing 12.5 μ L 2 × Taq Master Mix (Vazyme), 205 1 μL cDNA, and 0.4 μM of each primer. The primers used were 5'-GGAGACCCAAGCTGGCTAGT-3' 206 (forward) and 5'-AGACCGAGGAGAGGGTTAGG-3' (reverse), both of which are located within the 207 pcDNA3.1/V5-His-TOPO vector sequence. The PCR program had an initial denaturation step at 94°C 208 for 5 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and 209 extension at 72°C for 5 min, and a final extension step at 72°C for 7 min. RT-PCR products presenting 210 either a single band or multiple bands were excised from the agarose gel and then purified using a 211 Gel Extraction Kit (Omega Bio-Tek). The sequencing primers employed were identical to those used 212 for the RT-PCR analyses. Sequencing reactions were conducted using the BigDye Terminator v3.1 213 Cycle Sequencing Kit (Applied Biosystems). 214

215 Approximate estimate of relative expression levels of co-expressed WT and aberrant transcripts

- To estimate the relative expression levels of aberrantly spliced transcripts in comparison to WT 216
- 217 transcripts for variants that produced both types of transcripts, we utilized ImageJ [41].
- 218

219 The contribution of generative artificial intelligence to the writing process

- 220 We used ChatGPT-4 [42] to enhance the readability and linguistic quality of this manuscript. We take 221 full responsibility for the content presented herein.
- 222
- 223 Results

Retrospective correlation of FLGSA data with SpliceAI predictions for known SPINK1 coding SNVs 224

- 225 We initiated the study with a retrospective analysis involving known SPINK1 coding SNVs that had
- 226 previously undergone FLGSA analysis. All 27 such variants consistently yielded WT transcripts in the

8

- 227 FLGSA assay [7, 31]. Details of these variants, including their precomputed SpliceAI Δ scores by
- 228 Illumina [11], are provided in Table 1 (see the end of the manuscript).
- Among the 108 corresponding SpliceAI Δ scores, only one exceeded the threshold of 0.20,
- specifically, a DL Δ score of 0.29 (20 bp) for c.26T>G. It's important to note that this DL score was not
- 231 physiologically relevant, as the predicted donor loss pertains to the GT dinucleotide at SPINK1 coding
- 232 positions c.7_8. Additionally, it's worth mentioning that none of the four alternative SPINK1
- 233 transcript isoforms (NM_003122.5, NM_001354966.2, XM_047417625.1, and XM_047417626.1 [43])
- utilizes the c.7_8 GT dinucleotide as a splice donor site. The next highest score was a mere 0.11,
- specifically a DG score for c.29G>A. Therefore, except for the case of c.26T>G, a perfect correlation
- 236 was observed between the FLGSA-derived and SpliceAI-predicted data in the context of the subset of
- 237 known SPINK1 coding SNVs.
- 238

239 Selection of potential SPINK1 coding SNVs for FLGSA

240 Next, we aimed to select a new set of *SPINK1* coding SNVs for FLGSA analysis. We based our selection

on the Illumina precomputed SpliceAI scores (Supplementary Table S1). Adhering to the

242 methodological guidelines detailed in the *Methods* section, we carefully chose 35 SNVs. To enhance

clarity, we will elucidate the selection process within the context of the four exons. Details of the 35

- chosen SNVs, alongside their corresponding Illumina precomputed SpliceAI scores, are provided in
- 245 Table 1.

246 Exon 1, comprising 55 coding nucleotides, exhibited AG and AL scores of zero for all 165 possible 247 SNVs. As a result, our selection process relied on DG and DL scores. Initially, we included all three 248 possible SNVs at the terminal position of exon 1 (i.e., c.55G>A, c.55G>C, and c.55G>T), whose DG and 249 DL scores ranged from 0.33 to 0.51. Subsequently, from the remaining SNVs, we included the three 250 with the highest DG scores (i.e., c.11C>G, 0.44; c.15C>T, 0.52; and c.43T>G, 0.38), along with two 251 additional variants at c.43, specifically c.43T>C and c.43T>A. Regarding DL scores, those with positive values (referring to positions within either the 5'-UTR or coding sequence of exon 1) and some with 252 253 negative values (referring to positions within the coding sequence of exon 1) were deemed 254 physiologically irrelevant. Notably, all five variants with a physiologically relevant DL score of >0.10 255 (i.e., c.11C>G, 0.45; c.15C>T, 0.13; c.55G>A, 0.40; c.55G>C, 0.34; and c.55G>T, 0.51) also possessed a 256 DG score of at least 0.33, and hence, were already included in our analysis. Lastly, for the purpose of 257 comparison, we included all three possible SNVs at c.9, all of which were predicted to have a DG 258 score of 0.04.

Exon 2, encompassing 32 coding nucleotides, hosts 96 potential SNVs. Notably, two SNVs at the
 starting position (c.56) and all three SNVs at the final two positions (c.86 and c.87) of exon 2
 demonstrated AL and DL scores >0.20. As a result, we included all potential SNVs at these three

9

positions in the functional analysis. Additionally, the sole additional SNV meeting the criteria of both
AL and DL scores >0.20 was c.84A>G. Hence, we incorporated this SNV, along with the other two
possible SNVs at the c.84 position, into the functional analysis. Finally, four variants demonstrated a
single score surpassing 0.20. These included c.64G>T with an AL score of 0.22, c.65G>T with an AL
score of 0.31, c.80G>T with a DG score of 0.61, and c.85G>T with an AL score of 0.25. For the FLGSA
assay, we selected the latter three variants for inclusion.
Exon 3, comprising 107 coding nucleotides, contains 321 potential SNVs. Among the 1284

269 SpliceAI scores associated with these variants, most were zero. However, exceptions included an AG 270 score of 0.13 for c.92A>G and a DG score of 0.26 for c.178T>G. In our FLGSA analysis, we prioritized

271 c.178T>G. Additionally, we incorporated three SNVs at the beginning of exon 3 (c.88G>A, c.88G>C,

and c.88G>T) and two at its end (c.194G>C and c.194G>T, with the note that c.194G>A had been

273 previously analyzed in [7]).

Exon 4, with 46 coding nucleotides, contains 138 possible SNVs. All 552 corresponding SpliceAl Δ
scores consistently remained at or near zero, with a maximum of 0.05, except for two cases: an AL
score of 0.10 for c.195G>C and an AL score of 0.23 for c.195G>T. Since c.195 is the starting position
of exon 4, we included all three possible SNVs at this position for FLGSA.

278


279 FLGSA assay for the 35 prospectively selected SPINK1 coding SNVs

280 Then, we embarked on the functional characterization of the splicing impact of the aforementioned 281 35 prospective SPINK1 coding SNVs using the FLGSA assay. The outcomes, represented by RT-PCR 282 band patterns in agarose gel analysis, are detailed in Fig. 2. In accordance with our common practice 283 [27, 29, 30], we employed Sanger sequencing to determine the identity of RT-PCR bands whenever 284 possible. This step carried particular significance for two primary reasons: (i) a seemingly WT RT-PCR 285 band could differ from the genuine WT by only one or two base pairs [30, 32], and (ii) this 286 information was pivotal for comparison with SpliceAI-predicted splice-altering sites in instances of 287 aberrant splicing. Additionally, it's worth mentioning that the WT transcripts originating from cells 288 transfected with the variant expression vectors consistently contained the corresponding coding 289 SNVs.

However, we encountered challenges in sequencing several faint bands (e.g., the barely discernible band below the major band in c.11C>G; Fig. 2). These faint bands could potentially signify authentic aberrantly spliced transcripts or spurious amplifications. It is important to note two key considerations. Firstly, our prior investigation of 5' splice site GT>GC variants established that our FLGSA assay was capable of detecting as little as ~1% of normally spliced transcripts [32]. Secondly, we had previously postulated that a *SPINK1* variant is unlikely to have pathological relevance if it caused a <10% loss of

10

- normal function (or retained >90% normal function) [25]. Therefore, we excluded these barely visible 296
- 297 RT-PCR bands from further consideration.
- A concise summary of the FLGSA findings, including comparative levels of aberrant versus WT 298
- 299 transcripts where applicable, can be found in Table 1.
- 300



301

Figure 2. RT-PCR results for the FLGSA analysis of 35 potential SPINK1 coding variants. In all panels, 302 303 arrows indicate wild-type transcripts, all of which were confirmed by Sanger sequencing. FLGSA, fulllength gene splicing assay. RT-PCR, reverse transcription-PCR. 304

305

306

perpetuity. It is made available under a CC-BY-NC 4.0 International license .


11

307 Correlation of FLGSA data with SpliceAI predictions for the 35 prospectively analyzed SNVs

- Subsequently, we conducted a thorough analysis to correlate the FLGSA data generated for the
 prospectively examined 35 SNVs with their corresponding Illumina precomputed SpliceAI scores
 (Table 1). After discarding physiologically irrelevant DL scores linked to various SNVs in exon 1, we
- observed a significant pattern in relation to the threshold Δ scores of 0.20 and 0.80 [11]. Specifically,
- all variants with a Δ score not exceeding 0.20 exclusively produced WT transcripts. Conversely, every
- 313 variant with a Δ score above 0.80 consistently led to the production of aberrant variants.
- 314 Establishing a clear correlation between the presence or absence of aberrant transcripts and
- 315 intermediate Δ scores (0.20 to 0.80) was challenging. However, a notable pattern emerged upon
- analyzing Δ scores for SNVs at positions c.55, c.56, and c.86. Each of these positions underwent
- 317 FLGSA analysis, with at least two of the three possible SNVs at each position generating both
- aberrant and WT transcripts. For a more focused analysis, we will compare the DL scores associated
- with these SNVs. At position c.55, all three SNVs yielded both aberrant and WT transcripts (Table 1).
- Notably, the variant with the lowest DL score, c.55G>C (0.34), also had the lowest ratio of aberrant to
- WT transcripts. At c.56, the c.56G>A variant, with no scores above 0.20, produced only WT
- transcripts. In contrast, c.56G>C and c.56G>T, with DL scores of 0.29 and 0.46 respectively, yielded
- both transcript types, and their aberrant/WT transcript ratios aligned with their DL scores. Regarding
- 324 c.86, c.86A>C, which had the lowest DL score (0.23), did not produce aberrant transcripts.
- 325 Conversely, c.86A>G, with the highest DL score (0.67), resulted in a significantly higher aberrant/WT
- transcript ratio of 4.13/1. Interestingly, c.86A>T, with a lower DL score (0.57) than c.86A>G, led to a
- much lower aberrant/WT transcript ratio (1/5.31) in comparison.
- We then hypothesized that conducting a comprehensive cross-comparison of various events
 within the same exon context might yield valuable insights into the remaining intermediate Δ scores.
 We explored this hypothesis within the contexts of the four exons.
- 331
- 332 Exon 1
- All three SNVs at the last nucleotide of exon 1, c.55, exhibited DL scores ranging from 0.34 to 0.51 and DG scores between 0.33 and 0.37 (Table 1). Based on their corresponding mRNA positions, these SNVs were predicted to disrupt the physiological GT splice donor site at positions c.55+1_2 and activate an upstream cryptic splice donor site within exon 1 (i.e., the GT dinucleotide at position c.7_8) (Fig. 3a). This would result in a significantly shortened transcript that lacked the last 49 nucleotides (i.e., c.7 to c.55) of exon 1. Interestingly, our FLGSA assay detected an aberrant transcript that retained the first 140 bases of intron 1 (Fig. 2), due to the activation of a downstream cryptic GT
- 340 splice site located at the deep intron 1 region (precisely at c.55+141_142) (Fig. 3a).
- 341

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

12



342

343 Figure 3. Interpretation of the three c.55 SNVs and the c.11C>G variant in exon 1 by reference to 344 SpliceAI predictions and FLGSA results. a Illustration of the (partial) disruption of the physiological 5' splice donor site of SPINK1 intron 1 caused by the three potential SNVs at the last nucleotide of exon 345 1 (c.55). This disruption is shown in the context of the corresponding 9-bp 5' splice signal sequence, 346 which interacts with the 3'-GUCCAUUCA-5' sequence at the 5' end of U1snRNA. SpliceAI predicted this 347 disruption (DL scores, 0.34 to 0.51) and the activation of an upstream cryptic splice donor site within 348 exon 1 (DG scores, 0.33 and 0.37). However, our FLGSA assay revealed the activation of a downstream 349 cryptic splice donor site. Vertical lines indicate paired bases between the 9-bp 5' splice signal sequence 350 351 and the 5' end sequence of U1snRNA. The GT dinucleotides involved are highlighted in blue, with their 352 positions (in accordance with NM_001379610.1) indicated. The 9-bp 5' splice site signal sequence position weight matrices (PWM) were sourced from Leman et al. [44], an Open Access article 353 distributed under the terms of the Creative Commons Attribution Non-Commercial License. Note that 354 355 the 9-bp 5' splice signal sequences, whether in the context of the consensus sequence or SPINK1 sequences, are presented in DNA. b Illustration of the c.11C>G variant in the context of the 356 aforementioned upstream cryptic splice donor site. A dotted line represents the new base pairing 357 derived from the variant, enhancing the interaction between the 9-bp 5' splice signal sequence and 358 359 the 5' end sequence of U1snRNA.

360

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

13

361 We performed two additional analyses to address the discrepancy between in silico predictions 362 and experimental data. First, considering that the Illumina precomputed scores were created using a 363 maximum distance of 50 bp, we reevaluated the three possible c.55 SNVs using SpliceAI with an 364 extended distance of 10,000 bp and the hg38 sequence [40]. Although the resulting DG and DL scores showed slight variations compared to the Illumina precomputed scores (Supplementary Table S1), 365 366 they did not alter the predicted splicing outcomes. Second, we examined the predicted and 367 experimentally obtained cryptic GT donor site in the context of the 9-bp 5' splice signal sequence and 368 their pairing with the 3'-GUCCAUUCA-5' sequence at the 5' end of U1snRNA (see [32] and references 369 therein). Interestingly, the experimentally identified cryptic GT donor site was found within a 9-bp 5' 370 splice signal sequence that exhibited 8 bp complementarity with the 9 bp U1snRNA sequence. In 371 contrast, the *in silico* predicted cryptic GT donor site resided within a 9-bp 5' splice signal sequence 372 with only 6 bp complementarity to the 9 bp U1snRNA sequence (Fig. 3a). It's noteworthy that this in 373 silico predicted cryptic GT donor site coincides with the previously discussed false physiological GT 374 dinucleotide at position c.7 8, which was related to the DL score of the known c.26T>G variant (see 375 Retrospective correlation of FLGSA data with SpliceAI predictions for known SPINK1 coding SNVs). 376 Based on these new findings, we speculate that SpliceAI might have favored the nearby cryptic donor 377 site in exon 1 over the more distant cryptic donor site in intron 1.

378 Another variant in exon 1, c.11C>G, was predicted to induce a splicing effect similar to the three 379 potential c.55 SNVs based on the SpliceAl scores. Interestingly, it displayed even higher DG and DL 380 scores than those of the three potential c.55 SNVs (Table 1). However, the FLGSA analysis did not 381 reveal aberrant transcripts associated with the c.11C>G variant. As illustrated in Fig. 3b, c.11C>G 382 resides within the 9-bp 5' splice signal sequence linked to the previously mentioned cryptic 5' splice 383 GT donor site at positions c.7 8. Notably, it increased sequence complementarity with the 9-bp 384 U1snRNA sequence from 6 bp to 7 bp compared to the WT sequence. It's essential to highlight that, 385 in this scenario, the physiological intron 1 splice donor signal sequence remains unaltered. Bearing 386 this in mind, we conjecture that the enhanced sequence complementarity brought about by the 387 c.11C>G variant may have encountered difficulties in competing with the intact physiological intron 1 388 splice donor signal sequence, which exhibited 8 bp complementarity with U1snRNA (Fig. 3a).

Shifting our focus to other variants, let's consider c.15C>T, which had the highest DG score (0.52) among all possible coding SNVs in exon 1, but it only had a DL score of 0.13. We also have c.43T>G, which had a DG score of 0.38 but a DL score of zero. Importantly, neither of these variants resulted in the generation of aberrant transcripts (Table 1). Drawing parallels with the previously discussed c.11C>G variant, we propose that their predicted cryptic 5' splice donor sites, located within the coding sequence of exon 1, may not have effectively competed against the intact physiological intron 1 splice donor signal sequence.

14

396 Exons 2-4

Moving on to exons 2-4, two variants warrant closer examination: c.80G>T in exon 2 and c.178T>G in 397 398 exon 3. The former variant displayed a DG score of 0.61 but a DL score of only 0.10, while the latter 399 had a DG score of 0.26 but a DL score of zero (Table 1). Our FLGSA analysis did not produce any 400 aberrant transcripts associated with either of these variants. In line with our earlier observations 401 concerning variants in exon 1, such as c.11C>G and c.15C>T, we propose that the predicted cryptic 5' 402 splice donor sites may not have effectively competed with the intact physiological intron 2 and intron 403 3 splice donor signal sequences, respectively.

404

405 Extrapolation to unanalyzed SPINK1 coding SNVs

406 Finally, we addressed a critical question: Can we reasonably interpret the potential splicing effects of 407 the 658 SPINK1 coding variants that have not yet undergone functional analysis, based on insights 408 derived from the cross-correlation of FLGSA data and SpliceAI predictions of the 27 known and 35 409 newly analyzed SNVs? To accurately answer this question, we initially evaluated whether the Illumina 410 precomputed scores significantly deviated from those calculated using a distance of 10,000 bp and the hg38 sequence. Consequently, we manually acquired these latter scores from [40] for all SNVs 411 412 that underwent FLGSA. While we did observe slight disparities between the two datasets for many 413 SNVs (see Supplementary Table S1), it's crucial to emphasize that these variations were not expected 414 to result in any changes to the predicted splicing outcomes. Thus, we proceeded confidently, utilizing 415 the Illumina precomputed scores for our subsequent discussions within the contexts of the four 416 exons. Our primary focus remained on unanalyzed SNVs with a Δ score falling within the range of 417 0.20 to 0.30. This choice was motivated by two factors: (i) we have already included all variants with 418 a physiologically relevant Δ score exceeding 0.30 for FLGSA analysis, and (ii) a Δ score below 0.20 is 419 highly unlikely to impact splicing.

420

421 Exon 1

422 In exon 1, we identified nine unanalyzed SNVs with a physiologically plausible Δ score of ≥ 0.20 423 (c.3G>A, c.4A>C, c.11C>T, c.14G>T, c.28A>T, c.29G>T, c.36G>A, c.37G>T, and c.45G>T). Notably, 424 these scores consistently fall within the DG type, ranging from 0.20 to 0.24. Interestingly, all of these variants were predicted to have cryptic GT splice donor sites that coincide with the previously 425 426 discussed GT at c.7_8. Additionally, these variants exhibited low DL scores, spanning from 0 to 0.12. 427 When comparing these scores with those of the functionally analyzed exon 1 SNVs (see Table 1), we can conclude that none of these nine variants had any discernible impact on splicing. 428

- 429
- 430

15

Exon 2 431

- In exon 2, we identified only two unanalyzed SNVs with a physiologically plausible Δ score of ≥ 0.20 432
- 433 (c.64G>T and c.81A>T). Both scores are identical (0.22) and belong to the AL type. AG and DG scores
- 434 of the two variants are zero, while their DL scores are similar (0.11-0.13). Evaluation of the
- 435 corresponding mRNA positions associated with the AL and DL scores demonstrated that their
- predicted splicing outcomes would result in exon 2 skipping. 436
- 437 Of the functionally analyzed exon 2 variants, c.85G>T most closely resembles c.64G>T and
- 438 c.81A>T in terms of the Δ scores. However, c.85G>T had both slightly higher AL and DL scores than
- 439 c.64G>T and c.81A>T (AL, 0.25 vs. 0.22; DL, 0.17 vs. 0.11-0.13) and produced no aberrant transcripts.
- 440 c.65G>T is the next variant that most closely resembles c.64G>T and c.81A>T. c.65G>T had a higher
- 441 AL score (0.31) but equal DL score (0.17) compared to c.85G>T and generated aberrant transcripts.
- 442 However, the aberrant transcript was generated alongside the WT transcript, and its amount was
- 443 much less than that of the WT transcript (ratio of 1:5.16).
- 444 Based on this cross-comparison, we can conclude that c.64G>T and c.81A>T are highly unlikely to 445 generate aberrant transcripts.
- 446

447 Exons 3 and 4

- 448 In exon 3 and 4, none of the functionally analyzed SNVs generated aberrant transcripts. Moreover,
- 449 except for c.92A>G in exon 3, which had an AG score of 0.13, none of the unanalyzed SNVs had a
- 450 SpliceAI score exceeding 0.05. Consequently, all SNVs in these two exons were considered not to
- 451 impact splicing.
- 452

453 **Further validation**

- 454 While we had confidence in our above extrapolation, we opted for additional validation. Therefore,
- 455 we selected five variants with the highest scores among those not previously functionally analyzed
- within exons 1, 2, and 3 for FLGSA analysis. Specifically, they included two of the nine exon 1 variants 456
- 457 mentioned above (c.29G>T and c.37G>T), the two exon 2 variants mentioned earlier (c.64G>T and
- 458 c.81A>T), and the exon 3 variant c.92A>G (Table 2). As shown in Fig. 4, all five variants exclusively
- 459 produced WT transcripts, thereby validating our extrapolation.
- 460

461 Overview of splice-altering coding SNVs in the SPINK1 gene


- 462 Overall, our study covers 67 SPINK1 coding SNVs, accounting for 9.3% of all 720 possible coding SNVs
- and affecting 46 (19.2%) of 240 coding nucleotides. Out of these 67 SNVs, 12 were experimentally 463
- found to impact splicing. Based on a comprehensive cross-correlation of FLGSA-obtained and 464
- SpliceAI-predicted data, we conclude that all unanalyzed potential coding SNVs in the SPINK1 gene 465

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 16
- 466 are unlikely to have a significant effect on splicing. Therefore, the 12 splice-altering events identified
- in our study represent the totality of splice-altering events among the 720 potential coding SNVs in
- the *SPINK1* gene.
- 469
- 470 Table 2. Selected five SPINK1 coding SNVs for further validation*

Exon	Variant ^a		Illumina precomputed SpliceAI scores ^b					
	Nucleotide Amino acid		AG	AL	DG	DL		
	change	change						
1	c.29G>T	p.Ser10lle	0.00	0.00	0.24 (23 bp)	0.10 (-26 bp)		
1	c.37G>T	p.Ala13Ser	0.00	0.00	0.23 (31 bp)	0.08		
2	c.64G>T	p.Gly22*	0.00	0.22 (8 bp)	0.00	0.11 (-23 bp)		
2	c.81A>T	p.(=)	0.00	0.22 (25 bp)	0.00	0.13 (-6 bp)		
3	c.92A>G	p.Lys31Arg	0.13 (-1 bp)	0.00	0.00	0.00		

- 471 *Abbreviations:* AG, acceptor gain; AL, acceptor loss; DG, donor gain; DL, donor loss; FLGSA, full-length
 472 gene splicing assay; SNVs, single-nucleotide variants
- 473 *All five variants exclusively produced wild-type transcripts through FLGSA (see Fig. 4).
- 474 ^aSPINK1 mRNA reference sequence: NM_001379610.1.
- ^bIn parentheses: corresponding pre-mRNA positions are provided for Δ scores ≥0.10. Positive and
- 476 negative pre-mRNA positions indicate positions 5' and 3' to the variant position in terms of the
- 477 gene's sense strand.
- 478



479

Figure 4. RT-PCR results for the validation analysis of five potential *SPINK1* coding variants through
 FLGSA. Arrows indicate wild-type transcripts, all of which were confirmed by Sanger sequencing.
 FLGSA, full-length gene splicing assay. RT-PCR, reverse transcription-PCR.

- 483
- 484 Among the 12 splice-altering events, nine produced both WT and aberrant transcripts, while the
- 485 remaining three exclusively generated aberrant transcripts. These splice-altering SNVs were
- 486 predominantly found in exons 1 and 2, particularly affecting the first and/or last coding nucleotide of
- 487 each exon. Among the splice-altering events, 11 were missense variants, accounting for 2.17% of the

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

17

- 488 506 potential missense variants, while one was synonymous, accounting for 0.61% of the 164
- 489 potential synonymous variants (see Table 3).
- 490
- Table 3. Summary of splice-altering coding SNVs in the SPINK1 gene 491

Variant types	Total potential SNVs	Splice-altering SNVs	Percentage (b/a)
	(a)	(b)	
Translation initiation	9	0	0
codonª			
Missense	506	11	2.17
Synonymous	164	1	0.61
Nonsense	32	0	0
Translation	9	0	0
termination codon ^a			
Total	720		1.67

492 Abbreviation: SNVs, single-nucleotide variants

493 ^aSNVs occurring within either the translation initiation or termination codon are referred to simply as

"translation initiation codon" or "translation termination codon" variants. 494

495

Discussion 496

497 In this study, we leveraged the well-established FLGSA assay [7, 27-31] in conjunction with SpliceAI

498 [11] to explore the prospective interpretation of splicing effects for all potential coding SNVs within

499 the SPINK1 gene, following the structured progression outlined in Fig.1.

500 Our analysis unveiled intriguing discrepancies between SpliceAI predictions and the FLGSA data.

501 Notably, SpliceAl erroneously predicted that several exon 1 SNVs would disrupt a splice donor site

502 within the coding sequence of exon 1 (see Table 1). These predictions conflicted with two critical

503 pieces of evidence: Firstly, only one known SPINK1 transcript isoform, NM 001379610.1, is

504 expressed in the exocrine pancreas [22, 23]. Secondly, none of the other four alternative SPINK1

505 transcript isoforms [43] were found to utilize a GT dinucleotide within the exon 1 coding sequence as

506 a splice donor site. The convergence of these findings, along with the results of our FLGSA assay,

507 strongly suggests that these SpliceAI predictions were indeed spurious.

508 Another significant discrepancy centered around the splicing outcomes of the three SNVs at c.55, 509 specifically involving the last nucleotide of exon 1. SpliceAI predicted the activation of an upstream 510 cryptic GT dinucleotide at c.7 8, whereas our FLGSA assay identified the activation of a downstream cryptic GT dinucleotide located at c.55+141 142. Intriguingly, the SpliceAI-predicted cryptic GT 511

18

512 dinucleotide coincided with one of the aforementioned erroneous splice GT donor sites, highlighting a recurring issue with SpliceAI predictions in the context of exon 1 coding sequences. Notably, our 513 514 experimentally identified cryptic GT dinucleotide exhibited stronger complementarity with the 3'-GUCCAUUCA-5' sequence at the 5' end of U1snRNA, featuring eight complementary bases, in 515 contrast to the SpliceAI-predicted cryptic GT dinucleotide with only six complementary bases (refer 516 517 to Fig. 3a). It's important to mention that our experimentally identified cryptic GT dinucleotide is 518 situated more distantly (141 bp) from c.55 than the SpliceAI-predicted cryptic GT dinucleotide (47 519 bp), potentially explaining why the latter was not correctly predicted by SpliceAI. Additionally, it's 520 worth acknowledging that variants in exon 1 are not readily amenable to analysis through the 521 commonly used minigene assay [8], and the activation of cryptic donor or splice sites in deep intronic 522 regions may often elude detection via a minigene assay.

523 Except for the aforementioned discrepancies, we found a robust correlation between FLGSA data 524 and SpliceAI predictions, particularly concerning the 0.20 and 0.80 threshold scores and the findings 525 for all possible SNVs at c.55, c.56, and c.86. While the relationship between FLGSA data and SpliceAI 526 scores below 0.20 or above 0.80 tended to be straightforward, deciphering the correlation between 527 FLGSA data and intermediate SpliceAI scores within the range of 0.20 to 0.80 presented challenges. 528 Nevertheless, our efforts to correlate these intermediate SpliceAI scores with FLGSA findings yielded 529 intriguing insights. For instance, variants with intermediate SpliceAI scores, when leading to aberrant 530 transcripts, often produced a mix of aberrant and WT transcripts. Furthermore, in the case of all 531 possible SNVs at c.55, c.56, and c.86, intermediate SpliceAI scores seemed to correlate with the 532 aberrant/WT transcript ratio. These mutually reinforcing data were instrumental in guiding a cross-533 comparison concerning unanalyzed variants, allowing us to reasonably extrapolate that none of the 534 unanalyzed coding SNVs in the SPINK1 gene are likely to exert a significant effect on splicing.

535 To the best of our knowledge, this study represents the first attempt to prospectively interpret all 536 potential coding SNVs in a disease-associated gene. Our findings unveiled that within the SPINK1 537 gene, 2.17% of all potential missense variants, 0.61% of all potential synonymous variants, but none 538 of the potential nonsense variants have an impact on splicing. In total, 1.67% (12 out of 720) of all 539 potential coding SNVs in the SPINK1 gene were found to alter splicing.

540 Among the 12 splice-altering variants, five (c.84A>G, c.86A>G, c.87G>A, c.87G>C, and c.87G>T) led exclusively or predominantly to aberrant transcripts. These five variants can be classified as 541 542 "pathogenic" and would have been mislabeled as silent or missense variants without the FLGSA 543 assay. The remaining seven variants exhibited aberrant to WT transcript ratios ranging from 1/21.72 to 2.97/1. In all these cases, the aberrant transcripts—either retaining part of intron 1 or omitting the 544 545 entire exon 2—would yield a non-functional product. However, when the aberrant transcript ratio is

19

substantially lower than that of the WT transcript, the variant in question (e.g., c.55G>C with a ratioof 1/21.72) may not be of pathogenic significance.

548 It's important to acknowledge the limitations of our FLGSA assay. For instance, like the minigene

assay, our experiments required transfected cells, which may not always faithfully recapitulate *in vivo*

550 conditions. However, findings from correlation of our FLGSA data with SpliceAI and cross-

551 comparisons of our FLGSA data across different variants gave strong support to the validity of our

552 FLGSA assay.

553

554 **Conclusions**

555 By integrating the FLGSA assay with SpliceAI predictions, our study presents compelling evidence that

556 1.67% of potential *SPINK1* coding SNVs exert a discernible impact on splicing outcomes. Our findings

557 underscore the critical necessity of conducting splicing analysis within the broader genomic context

of the target gene, a perspective that can reveal splicing outcomes often missed by conventional

559 minigene assays. Additionally, we emphasize the inherent uncertainties associated with intermediate

560 SpliceAI scores (ranging from 0.20 to 0.80), highlighting the critical role of functional analysis in

variant interpretation. Finally, our approach offers potential implications for transitioning from

562 "retrospective" to "prospective" variant analysis in other disease genes, accelerating the full

realization of precision medicine in the whole exome sequencing or whole genome sequencing era.

564

565 **Funding**

566 This research was funded by the National Natural Science Foundation of China (81800569 to HW,

567 82000611 to J-HL, and 82000606 to X-YT), the Shanghai Pujiang Program (2020PJD061 to J-HL), the

568 Shanghai Sailing Program (20YF1459400 to X-YT). Support for this study also came from the Institut

569 National de la Santé et de la Recherche Médicale (INSERM), the Association des Pancréatites

570 Chroniques Héréditaires and the Association Gaétan Saleün, France. The funding bodies did not play

any role in the study design, collection, analysis, and interpretation of data or the writing of the

article and the decision to submit it for publication.

573

574 Authors' contributions

575 HW, JHL, XYT, and WBZ designed the study, conducted the experiments, and contributed to paper

576 writing. SS acquired the Illumina precomputed SpliceAI scores. EM, YF, GLC, and CF contributed to

577 the conception of the study. ZL was involved in study conception and coordinated the experiments.

578 JMC conceived the study, obtained the latest SpliceAI scores, and wrote the manuscript. All authors

579 participated in data review, revised the manuscript with critical intellectual input, approved the

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- submitted version, and agreed to be personally accountable for the author's own contributions and
- to ensure that questions related to the accuracy or integrity of any part of the work, even ones in
- which the author was not personally involved, are appropriately investigated, resolved, and the
- resolution documented in the literature.
- 584

585 Acknowledgements

- 586 The authors are grateful to GENEWIZ Biotech Co. (Suzhou, China) for their assistance in preparing the
- 587 variant expression vectors.
- 588

589 **References**

- Manning KS, Cooper TA. The roles of RNA processing in translating genotype to phenotype. Nat Rev Mol Cell
 Biol. 2017;18(2):102-14.
- Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that
 affect splicing. Nat Rev Genet. 2002;3(4):285-98.
- Sarkar A, Panati K, Narala VR. Code inside the codon: The role of synonymous mutations in regulating splicing machinery and its impact on disease. Mutat Res Rev Mutat Res. 2022;790:108444.
- Aicher JK, Jewell P, Vaquero-Garcia J, Barash Y, Bhoj EJ. Mapping RNA splicing variations in clinically
 accessible and nonaccessible tissues to facilitate Mendelian disease diagnosis using RNA-seq. Genet Med.
 2020;22(7):1181-90.
- 5. Wai HA, Lord J, Lyon M, Gunning A, Kelly H, Cibin P, et al. Blood RNA analysis can increase clinical diagnostic
 rate and resolve variants of uncertain significance. Genet Med. 2020;22(6):1005-14.
- 601 6. Gaildrat P, Killian A, Martins A, Tournier I, Frebourg T, Tosi M. Use of splicing reporter minigene assay to 602 evaluate the effect on splicing of unclassified genetic variants. Methods Mol Biol. 2010;653:249-57.
- Wu H, Boulling A, Cooper DN, Li ZS, Liao Z, Chen JM, et al. *In vitro* and *in silico* evidence against a significant
 effect of the *SPINK1* c.194G>A variant on pre-mRNA splicing. Gut. 2017;66(12):2195-6.
- 8. Lin JH, Wu H, Zou WB, Masson E, Fichou Y, Le Gac G, et al. Splicing outcomes of 5' splice site GT>GC variants
 that generate wild-type transcripts differ significantly between full-length and minigene splicing assays.
 Front Genet. 2021;12:701652.
- Fu XD, Ares M, Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev
 Genet. 2014;15(10):689-701.
- 610 10. Drexler HL, Choquet K, Churchman LS. Splicing kinetics and coordination revealed by direct nascent RNA
 611 sequencing through nanopores. Mol Cell. 2020;77(5):985-98.
- 612 11. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting
 613 splicing from primary sequence with deep learning. Cell. 2019;176(3):535-48.
- 614 12. Lord J, Baralle D. Splicing in the diagnosis of rare disease: advances and challenges. Front Genet.
 615 2021;12:689892.
- 616 13. Dawes R, Joshi H, Cooper ST. Empirical prediction of variant-activated cryptic splice donors using
 617 population-based RNA-Seq data. Nat Commun. 2022;13(1):1655.
- 618 14. Masson E, Zou WB, Pu N, Rebours V, Genin E, Wu H, et al. Classification of *PRSS1* variants responsible for
 619 chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN study group. Pancreatology.
 620 2023;23(5):491-506.
- 621 15. Walker LC, Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, et al. Using the ACMG/AMP framework
 622 to capture evidence related to predicted and observed impact on splicing: Recommendations from the
 623 ClinGen SVI Splicing Subgroup. Am J Hum Genet. 2023;110(7):1046-67.
- 16. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the
 interpretation of sequence variants: a joint consensus recommendation of the American College of Medical
 Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24.
- 627 17. Shendure J, Findlay GM, Snyder MW. Genomic medicine-progress, pitfalls, and promise. Cell.
- 628 2019;177(1):45-57.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 629 18. Starita LM, Ahituv N, Dunham MJ, Kitzman JO, Roth FP, Seelig G, et al. Variant interpretation: functional
 630 assays to the rescue. Am J Hum Genet. 2017;101(3):315-25.
- 631 19. Gasperini M, Starita L, Shendure J. The power of multiplexed functional analysis of genetic variants. Nat
 632 Protoc. 2016;11(10):1782-7.
- 633 20. Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, et al. Accurate classification of *BRCA1*634 variants with saturation genome editing. Nature. 2018;562(7726):217-22.
- Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, et al. Mutations in the gene encoding the serine
 protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 2000;25(2):213-6.
- 22. Yamamoto T, Nakamura Y, Nishide J, Emi M, Ogawa M, Mori T, et al. Molecular cloning and nucleotide
 sequence of human pancreatic secretory trypsin inhibitor (*PSTI*) cDNA. Biochem Biophys Res Commun.
 1985;132(2):605-12.
- 640 23. Horii A, Kobayashi T, Tomita N, Yamamoto T, Fukushige S, Murotsu T, et al. Primary structure of human
 641 pancreatic secretory trypsin inhibitor (*PSTI*) gene. Biochem Biophys Res Commun. 1987;149(2):635-41.
- 642 24. Hegyi E, Sahin-Tóth M. Genetic risk in chronic pancreatitis: the trypsin-dependent pathway. Dig Dis Sci.
 643 2017;62(7):1692-701.
- 644 25. Masson E, Zou WB, Genin E, Cooper DN, Le Gac G, Fichou Y, et al. Expanding ACMG variant classification
 645 guidelines into a general framework. Hum Genomics. 2022;16(1):31.
- 646 26. Boulling A, Chen JM, Callebaut I, Férec C. Is the *SPINK1* p.Asn34Ser missense mutation *per se* the true culprit
 647 within its associated haplotype? WebmedCentral GENETICS. 2012;3:WMC003084.
- 648 27. Zou WB, Boulling A, Masson E, Cooper DN, Liao Z, Li ZS, et al. Clarifying the clinical relevance of *SPINK1*649 intronic variants in chronic pancreatitis. Gut. 2016;65(5):884-6.
- 28. Zou WB, Masson E, Boulling A, Cooper DN, Li ZS, Liao Z, et al. Digging deeper into the intronic sequences of
 the SPINK1 gene. Gut. 2016;65(6):1055-6.
- 29. Zou WB, Wu H, Boulling A, Cooper DN, Li ZS, Liao Z, et al. *In silico* prioritization and further functional
 characterization of *SPINK1* intronic variants. Hum Genomics. 2017;11(1):7.
- 30. Tang XY, Lin JH, Zou WB, Masson E, Boulling A, Deng SJ, et al. Toward a clinical diagnostic pipeline for
 SPINK1 intronic variants. Hum Genomics. 2019;13(1):8.
- 31. Wu H, Boulling A, Cooper DN, Li ZS, Liao Z, Férec C, et al. Analysis of the impact of known *SPINK1* missense
 variants on pre-mRNA splicing and/or mRNA stability in a full-length gene assay. Genes (Basel).
 2017;8(10):263.
- 659 32. Lin JH, Tang XY, Boulling A, Zou WB, Masson E, Fichou Y, et al. First estimate of the scale of canonical 5'
 660 splice site GT>GC variants capable of generating wild-type transcripts. Hum Mutat. 2019;40(10):1856-73.
- 33. Kume K, Masamune A, Kikuta K, Shimosegawa T. [-215G>A; IVS3+2T>C] mutation in the SPINK1 gene causes
 exon 3 skipping and loss of the trypsin binding site. Gut. 2006;55(8):1214.
- 34. Chen JM, Lin JH, Masson E, Liao Z, Férec C, Cooper DN, et al. The experimentally obtained functional impact
 assessments of 5' splice site GT>GC variants differ markedly from those predicted. Curr Genomics.
 2020;21(1):56-66.
- 35. Ota Y, Masamune A, Inui K, Kume K, Shimosegawa T, Kikuyama M. Phenotypic variability of the homozygous
 IVS3+2T>C mutation in the serine protease inhibitor Kazal type 1 (*SPINK1*) gene in patients with chronic
 pancreatitis. Tohoku J Exp Med. 2010;221(3):197-201.
- 36. Venet T, Masson E, Talbotec C, Billiemaz K, Touraine R, Gay C, et al. Severe infantile isolated exocrine
 pancreatic insufficiency caused by the complete functional loss of the *SPINK1* gene. Hum Mutat.
 2017;38(12):1660-5.
- 37. Morales J, Pujar S, Loveland JE, Astashyn A, Bennett R, Berry A, et al. A joint NCBI and EMBL-EBI transcript
 set for clinical genomics and research. Nature. 2022;604(7905):310-5.
- 38. Illumina precomputed SpliceAI scores. <u>https://github.com/Illumina/SpliceAI</u> (version 1.3). Accessed 18
 February 2020.
- 676 39. SpliceAl Virtual website. <u>https://mobidetails.iurc.montp.inserm.fr/MD</u>. Accessed 29 September 2023.
- 40. SpliceAl Lookup. <u>https://spliceailookup.broadinstitute.org/</u>. Accessed 16 October 2023.
- 678 41. ImageJ. <u>https://imagej.net/</u>. Accessed 18 October 2023.
- 679 42. ChatGPT-4. <u>https://chat.openai.com/</u>. Last accessed 09 November 2023.
- 680 43. SPINK1. <u>https://www.ncbi.nlm.nih.gov/gene/6690</u>. Accessed 16 October 2023.
- 44. Leman R, Gaildrat P, Gac GL, Ka C, Fichou Y, Audrezet MP, et al. Novel diagnostic tool for prediction of
 variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international
- 683 collaborative effort. Nucleic Acids Res. 2018;46(15):7913-23.
- 684

Exon	Variant ^a		Illumina precomputed SpliceAl scores ^b				Generation of aberrant transcripts as	Study
	Nucleotide	Amino acid	AG	AL	DG	DL	determined by FLGSA ^c	
	change	change						
1	c.9A>C	p.Val3Val	0.00	0.00	0.04	0.55 (3 bp) ^d	No	This study
1	c.9A>G	p.Val3Val	0.00	0.00	0.04	0.54 (3 bp) ^d	No	This study
1	c.9A>T	p.Val3Val	0.00	0.00	0.04	0.55 (3 bp) ^d	No	This study
1	c.11C>G	p.Thr4Arg	0.00	0.00	0.44 (5 bp)	0.45 (-44 bp)	No	This study
1	c.15C>T	p.Gly5Gly	0.00	0.00	0.52 (2 bp)	0.13 (-40 bp)	No	This study
1	c.26T>G	p.Leu9Arg	0.00	0.00	0.03	0.29 (20 bp) ^d	No	[31]
1	c.29G>A	p.Ser10Asn	0.00	0.00	0.11 (23 bp)	0.03	No	[31]
1	c.36G>C	p.Leu12Phe	0.00	0.00	0.02	0.10 (30 bp) ^d	No	[31]
1	c.41T>C	p.Leu14Pro	0.00	0.00	0.01	0.04	No	[31]
1	c.41T>G	p.Leu14Arg	0.00	0.00	0.02	0.09 (35 bp) ^d	No	[31]
1	c.43T>A	p.Leu15Met	0.00	0.00	0.02	0.12 (37 bp) ^d	No	This study
1	c.43T>C	p.Leu15=	0.00	0.00	0.03	0.14 (37 bp) ^d	No	This study
1	c.43T>G	p.Leu15Val	0.00	0.00	0.38 (1 bp)	0.00	No	This study
1	c.55G>A	p.Gly19Ser	0.00	0.00	0.36 (49 bp)	0.40 (0 bp)	Yes (Intron 1 retention ^e /WT: 1/9.03)	This study
1	c.55G>C	p.Gly19Arg	0.00	0.00	0.33 (49 bp)	0.34 (0 bp)	Yes (Intron 1 retention ^e /WT: 1/21.72)	This study
1	c.55G>T	p.Gly19Cys	0.00	0.00	0.37 (49 bp)	0.51 (0 bp)	Yes (Intron 1 retention ^e /WT: 1/9.38)	This study
2	c.56G>A	p.Gly19Asp	0.01	0.10 (0 bp)	0.00	0.07	No	This study
2	c.56G>C	p.Gly19Ala	0.01	0.40 (0 bp)	0.00	0.29 (-31 bp)	Yes (E2 skipping/WT: 1/1.32)	This study
2	c.56G>T	p.Gly19Val	0.01	0.61 (0 bp)	0.00	0.46 (-31 bp)	Yes (E2 skipping/WT: 2.97/1)	This study
2	c.65G>T	p.Gly22Val	0.00	0.31 (9 bp)	0.00	0.17 (-22 bp)	Yes (E2 skipping/WT: 1/5.16)	This study
2	c.75C>T	p.Ser25=	0.00	0.02	0.00	0.02	No	[31]

Table 1. FLGSA data and Illumina precomputed SpliceAI Δ scores for 27 known and 35 potential *SPINK1* coding SNVs

2	c.80G>T	p.Gly27Val	0.00	0.09	0.61 (2 bp)	0.10 (-7 bp)	No	This study
2	c.84A>C	p.Arg28Ser	0.00	0.01	0.00	0.00	No	This study
2	c.84A>G	p.Arg28=	0.00	0.49 (28 bp)	0.00	0.25 (-3 bp)	Yes (E2 skipping/WT: 10.80/1)	, This study
2	c.84A>T	p.Arg28Ser	0.00	0.04	0.01	0.02	No	This study
2	c.85G>T	p.Glu29*	0.00	0.25 (29 bp)	0.00	0.17 (-2 bp)	No	This study
2	c.86A>C	p.Glu29Ala	0.00	0.51 (30 bp)	0.01	0.23 (-1 bp)	No	This study
2	c.86A>G	p.Glu29Gly	0.00	0.84 (30 bp)	0.00	0.67 (-1 bp)	Yes (E2 skipping/WT: 4.13/1)	This study
2	c.86A>T	p.Glu29Val	0.00	0.81 (30 bp)	0.00	0.58 (-1 bp)	Yes (E2 skipping/WT: 1/5.31)	This study
2	c.87G>A	p.Glu29=	0.00	0.87 (31 bp)	0.00	0.93 (0 bp)	Yes (Complete E2 skipping)	This study
2	c.87G>C	p.Glu29Asp	0.00	0.84 (31 bp)	0.01	0.93 (0 bp)	Yes (Complete E2 skipping)	This study
2	c.87G>T	p.Glu29Asp	0.00	0.88 (31 bp)	0.02	0.93 (0 bp)	Yes (Complete E2 skipping)	This study
3	c.88G>A	p.Ala30Thr	0.00	0.00	0.00	0.00	No	This study
3	c.88G>C	p.Ala30Pro	0.00	0.00	0.00	0.00	No	This study
3	c.88G>T	p.Ala30Ser	0.00	0.01	0.00	0.00	No	This study
3	c.101A>G	p.Asn34Ser	0.00	0.00	0.00	0.00	No	[31]
3	c.110A>G	p.Asn37Ser	0.00	0.00	0.00	0.00	No	[31]
3	c.123G>C	p.Lys41Asn	0.00	0.00	0.00	0.00	No	[31]
3	c.126A>G	p.lle42Met	0.00	0.00	0.00	0.00	No	[31]
3	c.133C>T	p.Pro45Ser	0.00	0.00	0.00	0.00	No	[31]
3	c.137T>A	p.Val46Asp	0.00	0.00	0.00	0.00	No	[31]
3	c.143G>A	p.Gly48Glu	0.00	0.00	0.00	0.00	No	[31]
3	c.150T>G	p.Asp50Glu	0.00	0.00	0.00	0.00	No	[31]
3	c.160T>C	p.Tyr54His	0.00	0.00	0.00	0.00	No	[31]
3	c.163C>T	p.Pro55Ser	0.00	0.00	0.00	0.00	No	[31]
3	c.174C>T	p.Cys58=	0.00	0.00	0.00	0.00	No	[31]

3	c.178T>G	p.Leu60Val	0.00	0.00	0.26 (1 bp)	0.00	No	This study
3	c.190A>G	p.Asn64Asp	0.00	0.00	0.00	0.00	No	[31]
3	c.193C>T	p.Arg65Trp	0.00	0.00	0.00	0.00	No	[31]
3	c.194G>A	p.Arg65Gln	0.00	0.00	0.00	0.00	No	[7]
3	c.194G>C	p.Arg65Pro	0.00	0.00	0.00	0.00	No	This study
3	c.194G>T	p.Arg65Leu	0.00	0.00	0.00	0.00	No	This study
4	c.195G>A	p.Arg65=	0.00	0.03	0.00	0.00	No	This study
4	c.195G>C	p.Arg65=	0.00	0.10 (0 bp)	0.00	0.00	No	This study
4	c.195G>T	p.Arg65=	0.00	0.23 (0 bp)	0.00	0.00	No	This study
4	c.198A>C	p.Lys66Asn	0.01	0.00	0.00	0.00	No	[31]
4	c.199C>T	p.Arg67Cys	0.00	0.01	0.00	0.00	No	[31]
4	c.200G>A	p.Arg67His	0.00	0.00	0.00	0.00	No	[31]
4	c.203A>G	p.Gln68Arg	0.01	0.00	0.00	0.00	No	[31]
4	c.206C>T	p.Thr69Ile	0.00	0.01	0.00	0.00	No	[31]
4	c.231G>A	p.Gly77=	0.01	0.00	0.00	0.00	No	[31]
4	c.236G>T	p.Cys79Phe	0.00	0.02	0.00	0.00	No	[31]

686 *Abbreviations:* AG, acceptor gain; AL, acceptor loss; DG, donor gain; DL, donor loss; FLGSA, full-length gene splicing assay; SNVs, single-nucleotide variants;

687 WT, wild-type

688 ^aSPINK1 mRNA reference sequence: NM_001379610.1.

^bIn parentheses: corresponding pre-mRNA positions are provided for Δ scores ≥0.10. Positive and negative pre-mRNA positions indicate positions 5' and 3'

690 to the variant position in terms of the gene's sense strand.

691 ^cIn parentheses: in case of the generation of aberrant transcripts, the nature of the aberrant transcripts and the ratio of aberrant transcripts to WT

692 transcripts are indicated.

^dConsidered not to be physiologically relevant as the predicted donor loss is situated within exon 1 of the *SPINK1* gene.

^eRetention of the first 140 bases of intron 1.